All the news

Most people who inject drugs completed treatment with sofosbuvir/velpatasvir (Epclusa) and achieved sustained virological response (SVR) in a real-world setting, even if they had interruptions in therapy, according to a presentation at the AASLD ...

Lack of privacy, lack of peer support and lack of harm reduction are perceived as the biggest barriers to improving the uptake of direct-acting antiviral treatment for hepatitis C among prisoners, a qualitative ...

Direct-acting antiviral treatment is highly effective at curing hepatitis C in people who inject drugs and in people receiving opioid substitution therapy (OST), a systematic review and meta-analysis of 38 studies published ...

The proportion of people with chronic hepatitis C virus (HCV) infection who receive antiviral treatment has increased substantially since the introduction of direct-acting antivirals (DAAs), investigators from the United States report in ...

Offering hepatitis C treatment and opioid substitution therapy with buprenorphine at the same location can help increase adherence and reduce harms associated with injection drug use, according to findings from the ANCHOR study ...

An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area, ...

Efforts to eliminate viral hepatitis in Europe will need to focus on people who inject drugs and prisoners if European Union nations are to achieve the World Health Organization target ...